Overall, our data suggest that therapeutic strategies such as efficient delivery of ZNF322A interference RNAs or treatment of targeted inhibitors of ZNF322A downstream post-transcriptional modification can be a potential molecular therapeutic method for lung cancer in the future. This evidence concerns the gene ZNF322 and lung carcinoma.